1. Zhang H, Yang T, Wu M and Shen F: Intrahepatic cholangio‑ carcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett 379: 198‑205, 2016.
2. Doherty B, Nambudiri VE and Palmer WC: Update on the diag‑ nosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 19: 2, 2017.
3. Blechacz B and Gores GJ: Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology 48: 308‑321, 2008.
4. Yugawa K, Itoh S, Kurihara T, Yoshiya S, Mano Y, Takeishi K, Harada N, Ikegami T, Soejima Y, Mori M and Yoshizumi T: Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma. Am J Surg 218: 952‑958, 2019.
5. Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, et al: Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the liver cancer study group of Japan. Cancer 122: 61‑70, 2016.
6. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA and Henson PM. A receptor for phosphatidylserine‑specific clear‑ ance of apoptotic cells. Nature 405: 85‑90, 2000.
7. Chang B, Chen Y, Zhao Y and Bruick RK: JMJD6 is a histone arginine demethylase. Science 318: 444‑447, 2007.
8. Unoki M, Masuda A, Dohmae N, Arita K, Yoshimatsu M, Iwai Y, Fukui Y, Ueda K, Hamamoto R, Shirakawa M, et al: Lysyl 5‑hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6). J Biol Chem 288: 6053‑6062, 2013.
9. Yang J, Chen S, Yang Y, Ma X, Shao B, Yang S, Wei Y and Wei X: Jumonji domain‑containing protein 6 protein and its role in cancer. Cell Prolif 53: e12747, 2020.
10. Nolz JC: Molecular mechanisms of CD8(+) T cell trafficking and localization. Cell Mol Life Sci 72: 2461‑2473, 2015.
11. Farhood B, Najafi M and Mortezaee K: CD8+ cytotoxic T lympho‑ cytes in cancer immunotherapy: A review. J Cell Physiol 234: 8509‑8521, 2019.
12. Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Toshima T, Harada N, Kohashi K, Oda Y and Mori M: Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: Association with tumor‑infiltrating lymphocytes. Mod Pathol 34: 798‑807, 2021.
13. Asahi Y, Hatanaka KC, Hatanaka Y, Kamiyama T, Orimo T, Shimada S, Nagatsu A, Sakamoto Y, Kamachi H, Kobayashi N, et al: Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahe‑ patic cholangiocarcinoma. Surg Today 50: 931‑940, 2020.
14. Ronnekleiv‑Kelly SM and Pawlik TM: Staging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 6: 35‑43, 2017.
15. Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM and Calderaro J: PD‑L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 8: 24644‑24651, 2017.
16. Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y and Mori M: CMTM6 stabilizes PD‑L1 expression and is a new prognostic impact factor in hepatocellular carcinoma. Hepatol Commun 5: 334‑348, 2020.
17. Berardo C, Siciliano V, Di Pasqua LG, Richelmi P, Vairetti M and Ferrigno A: Comparison between Lipofectamine RNAiMAX and GenMute transfection agents in two cellular models of human hepatoma. Eur J Histochem 63: 3048, 2019.
18. Izumi T, Sakata K, Okuzaki D, Inokuchi S, Tamura T, Motooka D, Nakamura S, Ono C, Shimokawa M, Matsuura Y, et al: Characterization of human pegivirus infection in liver transplan‑ tation recipients. J Med Virol 91: 2093‑2100, 2019.
19. Shimokawa M, Yoshizumi T, Itoh S, Iseda N, Sakata K, Yugawa K, Toshima T, Harada N, Ikegami T and Mori M: Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma. Cancer Sci 111: 1228‑1240, 2020.
20. Feng M, Pan Y, Kong R and Shu S: Therapy of primary liver cancer. Innovation (Camb) 1: 100032, 2020.
21. Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, et al: LSD1 abla‑ tion stimulates anti‑tumor immunity and enables checkpoint blockade. Cell 174: 549‑563.e19, 2018.
22. Wan J, Liu H, Yang L, Ma L, Liu J and Ming L: JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. Int J Cancer 144: 2489‑2500, 2019.
23. Wong M, Sun Y, Xi Z, Milazzo G, Poulos RC, Bartenhagen C, Bell JL, Mayoh C, Ho N, Tee AE, et al: JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nat Commun 10: 3319, 2019.
24. Wang F, He L, Huangyang P, Liang J, Si W, Yan R, Han X, Liu S, Gui B, Li W, et al: JMJD6 promotes colon carcinogen‑ esis through negative regulation of p53 by hydroxylation. PLoS Biol 12: e1001819, 2014.
25. Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, Toshima T, Harada N, Ikegami T, Soejima Y, et al: Impact of immune response on outcomes in hepatocellular carcinoma: Association with vascular formation. Hepatology 72: 1987‑1999, 2020.
26. Yugawa K, Itoh S, Iseda N, Kurihara T, Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, et al: Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associ‑ ated with alterations of metabolic activity and immune status. Sci Rep 11: 5845, 2021.
27. Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y, et al: PD‑L1 is upregulated by simultaneous amplifica‑ tion of the PD‑L1 and JAK2 genes in non‑small cell lung cancer. J Thorac Oncol 11: 62‑71, 2016.
28. Lu C, Paschall AV, Shi H, Savage N, Waller JL, Sabbatini ME, Oberlies NH, Pearce C and Liu K: The MLL1‑H3K4me3 axis‑mediated PD‑L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst 109: djw283, 2017.
29. Gong J, Chehrazi‑Raffle A, Reddi S and Salgia R: Development of PD‑1 and PD‑L1 inhibitors as a form of cancer immuno‑ therapy: A comprehensive review of registration trials and future considerations. J Immunother Cancer 6: 8, 2018.
論文の公開元へ
